An Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Alzheimer's Disease (Study SNK01-AD02)
Latest Information Update: 20 Nov 2025
At a glance
- Drugs Troculeucel (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors NKGen Biotech
Most Recent Events
- 20 Nov 2025 New trial record